Compare Levi Strauss & Co. (LEVI) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Levi Strauss & Co. vs Moderna, Inc. — how do they compare? Levi Strauss & Co. trades at $22.59 (market cap $8.75B), while Moderna, Inc. trades at $63.57 (market cap $24.18B). The key difference: Moderna, Inc. is far larger — about 2.8× Levi Strauss & Co.'s market cap, and Levi Strauss & Co. pays a 2.81% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| LEVI | MRNA | |
|---|---|---|
Market Cap | $8.75B | $24.18B |
Sector | Consumer Cyclical | Health |
52-Week High | $25.53 | $81.80 |
52-Week Low | $17.92 | $22.36 |
Enterprise Value | $10.07B | $20.33B |
Dividend Yield | 2.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Levi Strauss (LEVI) trades at $22.57, down 4.32% amid a recent cybersecurity breach disclosure. The stock maintains strong fundamentals with a 9.66% net margin and 29.31% ROE, supported by three consecutive quarterly earnings beats. Technical indicators show mixed signals with bearish moving averages but oversold RSI conditions. Analyst consensus remains strongly bullish with a $27.88 price target representing 23.5% upside potential.
Despite near-term cybersecurity concerns, Levi's demonstrates robust DTC growth and digital transformation success. The company's raised 2026 outlook and dividend increase signal confidence, though execution risks and tariff pressures warrant monitoring. Current valuation at 16.24 P/E offers reasonable entry for long-term investors seeking exposure to the iconic brand's turnaround story.
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
